Joseph Belanoff Sells 26,198 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) CEO Joseph Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total value of $1,311,733.86. Following the transaction, the chief executive officer owned 2,918,326 shares in the company, valued at $146,120,582.82. This trade represents a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $37.60 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The stock has a 50-day simple moving average of $37.53 and a two-hundred day simple moving average of $60.76. The firm has a market capitalization of $4.00 billion, a PE ratio of 45.85 and a beta of 0.29. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The company had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same period last year, the business earned $0.26 EPS. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. Analysts forecast that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer is a material commercial catalyst that triggered the earlier sharp rally; approval creates a new revenue pathway and is the primary reason investors re‑rated the stock this week. FDA approval report
• Positive Sentiment: Broker/analyst support: Wolfe Research upgraded CORT (from underperform to peer‑perform) and other brokers (Truist, Canaccord) have issued bullish/strong‑buy views or raised targets, which can sustain buying interest as the market models new sales upside. Wolfe Research upgrade
• Neutral Sentiment: Market structure/volatility: trading halts and large intraday prints accompanied the approval-driven move — expect continued high volume and price swings as investors reprice expectations for launch and uptake. Market reaction coverage
• Neutral Sentiment: Consensus/ratings mix: some outlets show a “moderate buy” brokerage consensus; analysts remain mixed on valuation as the market weighs launch potential vs. prior execution and study data. Broker consensus report
• Negative Sentiment: Legal risk: multiple law firms have filed shareholder alerts and class actions alleging that Corcept misled investors about regulatory issues and patent matters; these suits (and the referenced FDA rejection / federal court patent loss claims) create potential liability, discovery risk and distraction for management. Hagens Berman class‑action alert
• Negative Sentiment: Insider selling: a recent disclosed sale by an insider reduced holdings significantly; while not proof of negative outlook, such sales can weigh on sentiment when paired with litigation headlines. Insider sale filing
• Negative Sentiment: Analyst divergence / forecast cuts: some firms have tempered long‑term estimates or issued cautious notes (e.g., a pessimistic forecast from HC Wainwright in recent coverage), underscoring uncertainty around peak sales and reimbursement. HC Wainwright coverage

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Torren Management LLC bought a new position in Corcept Therapeutics in the 4th quarter worth approximately $25,000. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics during the third quarter valued at approximately $25,000. Clearstead Advisors LLC lifted its holdings in shares of Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after buying an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new position in shares of Corcept Therapeutics in the fourth quarter worth $31,000. Finally, Hantz Financial Services Inc. boosted its position in shares of Corcept Therapeutics by 113.7% during the fourth quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 524 shares during the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CORT. HC Wainwright lowered their price target on shares of Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. UBS Group began coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price on the stock. Finally, Canaccord Genuity Group upped their target price on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $77.67.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.